MAPT and Alzheimer disease: Currently, standard specific AD diagnosis is based on the determination of protein peptides (β-amyloid42, tau), by immunoassay (ELISA technique), in invasively obtained cerebrospinal fluid sampling (CSF) and the expensive brain amyloid PET exams [3].